Bicara Therapeutics Inc. (BCAX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Bicara Therapeutics Inc. (BCAX) closed at USD 17.34 on 2026-10-14, a change of +1.5 % over the past year, with a market capitalization of USD 1.17B.

Bicara Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Bicara Therapeutics Inc. key figures

Previous close

USD 17.34 (2026-10-14)

1-year change

+1.5 %

Market cap

USD 1.17B

Enterprise value

USD 669.87M

P/E ratio (trailing)

-5.63

P/E ratio (forward)

-5.01

EPS (trailing)

-3.13

EPS (forward)

-3.52

PEG ratio

n/a

Price to book

2.48

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

16.85

Employees

103

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Bicara Therapeutics Inc.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Bicara Therapeutics Inc. and compare it with other stocks.